The Neurofibromatoses Type I Pipeline (Von Recklinghausen’s Disease) H1 2017 is the latest report published at ReportsnReports in Genetic Disorders category. The Neurofibromatoses Type I (Von Recklinghausen’s Disease) Pipeline Market Report encapsulates all the dormant and discontinued pipeline projects with latest news and press release.
Neurofibromatosis type 1 (NF1), also called von Recklinghausen's disease, is a rare genetic disorder characterized by the development of multiple noncancerous (benign) tumors of nerves and skin (neurofibromas). This is transmitted on chromosome 17 and is caused by mutation of the NF1 gene. Symptoms include liver enlargement, glioma, Lisch nodules and pheochromocytoma. Treatment includes pain medications, surgery, radiation therapy and chemotherapy.
Get Discount on this Research Report at http://www.reportsnreports.com/contacts/discount.aspx?name=1088695
The Pharmaceutical and Healthcare latest pipeline guide Neurofibromatoses Type I (Von Recklinghausen’s Disease) Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Neurofibromatoses Type I (Von Recklinghausen’s Disease) (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
Neurofibromatoses Type I (Von Recklinghausen’s Disease)
Companies Involved in Therapeutics Development
Alexion Pharmaceuticals Inc
Array BioPharma Inc
AstraZeneca Plc
Celldex Therapeutics Inc
Inquire more on this Research Report at http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=1088695
Neurofibromatoses Type I (Von Recklinghausen’s Disease) (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Neurofibromatoses Type I (Von Recklinghausen’s Disease) (Genetic Disorders).
- The pipeline guide reviews pipeline therapeutics for Neurofibromatoses Type I (Von Recklinghausen’s Disease) (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Neurofibromatoses Type I (Von Recklinghausen’s Disease) (Genetic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Neurofibromatoses Type I (Von Recklinghausen’s Disease) (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Neurofibromatoses Type I (Von Recklinghausen’s Disease) (Genetic Disorders)
Purchase this research report Direct from http://www.reportsnreports.com/purchase.aspx?name=1088695
List of Tables.

Number of Products under Development for Neurofibromatoses Type I (Von Recklinghausen’s Disease), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Pipeline by Alexion Pharmaceuticals Inc, H1 2017
Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Pipeline by Array BioPharma Inc, H1 2017
Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Pipeline by AstraZeneca Plc, H1 2017
Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Pipeline by Celldex Therapeutics Inc, H1 2017
Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Dormant Projects, H1 2017
About Us:
ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. Order report by calling ReportsnReports.com at +1 888 391 5441 OR send an email on [email protected] with your contact details.